Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 5%, reaching a new high of HKD 40.5, following the announcement of a multi-year research collaboration with Servier worth USD 888 million [1] Company Summary - Insilico Medicine's stock increased by 5.56% to HKD 40.26, with a trading volume of HKD 52.11 million [1] - The collaboration with Servier focuses on utilizing Insilico's AI platform, Pharma.AI, to identify and develop new therapeutic drugs targeting challenging oncology areas [1] - Insilico is eligible for an upfront payment of up to USD 32 million and milestone payments during the research phase, while Servier will lead clinical validation and commercialization [1] Industry Summary - According to recent research from Xiangcai Securities, AI technology has found suitable applications in various stages of the pharmaceutical process, demonstrating significant potential [1] - The report highlights that AI's underlying innovations in drug development are crucial in the increasingly competitive landscape of innovative drug research [1]
英矽智能再涨超5%创新高 近日宣布与施维雅达成8.88亿美元合作